Important note: Information in this article was accurate in July 2008. The state of the art may have changed since the publication date.
Access to generic efavirenz in South Africa: MSD agrees to grant licenses on reasonable terms
HIV Treat Bull - 2008 July-August;9(7/8):
Even though efavirenz is not the preferred first-line option for treatment in South Africa, being reserved for nevirapine intolerance or contraindication, it accounts for over 60% of the total South African ARV drug budget.
Legal action from community groups has resulted in the manufacturer making significant changes to address efavirenz supply and cost. [1]
Acting on behalf of TAC, the AIDS Law Project (ALP) lodged a complaint with the Competition Commission of South Africa in late 2007 alleging that MSD (Pty) Ltd – the South African subsidiary of multinational drug company Merck – was unlawfully refusing to license the antiretroviral (ARV) medicine efavirenz (EFV) on reasonable terms. [2]
In a statement on I June, TAC recognise that MSD is now no longer acting in an anticompetitive way, and that this paves the way for the market entry of a wide range of affordable efavirenz products.
According to the ALP’s records and recent correspondence from the Commission, MSD has:
On the basis of these significant developments, the Commission believes that there is no reason to refer the complaint to the Competition Tribunal for adjudication on what is now largely a historical complaint.
In practical terms, this means that there are now a sufficient number of competitors to ensure that efavirenz prices are kept as low as is reasonably possible. It also means that the public sector, which until relatively recently was paying 64 cents in every rand spent on first-line ARV treatments for efavirenz alone, can now choose to procure from up to five suppliers.
This also has the potential to enable the numerous co-packaged and co-formulated generic products commonly used in sub-Saharan Africa to be able to be used in South Africa.
Impact on price reductions
When TAC and the ALP first started to engage MSD on this issue as far back as May 2002, the company sold a year’s supply of EFV for one adult for US$500. That price has dropped significantly. Today, MSD’s best international price for a year’s supply is US$237.25. In contrast, the best international price for a generic equivalent of proven quality, safety and efficacy is US$150. In the South African private sector, MSD’s EFV sells for R166.90 (VAT inclusive) for a 30 days’ supply. In contrast, the cheapest registered generic equivalent sells for R136.80. These prices are expected to drop even further.
Price differentials in respect of FDCs are even greater. MSD has committed to sell Atripla at US$613.20 per patient per year. In contrast, the Clinton Foundation HIV/AIDS Initiative (CHAI) has managed to secure a commitment from a reputable Indian company to bring generic TDF/FTC/EFV to market for only US$349 per patient per year. The same company has also committed to bringing generic TDF/3TC/EFV – which is considered as therapeutically equivalent to the FTC version of the FDC – for US$299 per patient per year. South Africa is entitled to purchase drugs through CHAI.
References
‘TAC complaint increases access to efavirenz: MSD finally agrees to grant licenses on reasonable terms’. TAC statement: (1 June 2008).
2008-07-10
IB080907-06
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.